

# Curriculum Vitae – Silke Cameron

- Seit 06/17    Chefärztin, Abteilung für Gastroenterologie und allg. Innere Medizin, Klinikum Hann. Münden
- Seit 09/16    Leitung Arbeitsgruppe Kampo Medizin, Klinik für Gastroenterologie und Gastrointestinale Onkologie, Universitätsmedizin Göttingen
- 08/10-06/17   Oberärztin, Schwerpunkt gastrointestinale Onkologie; Abt. Gastroenterologie, UMG
- 07/2015       Habilitation (venia legendi: Innere Medizin): Untersuchungen zum Mikroenvironment gastrointestinaler Stromatumoren (GIST)
- 04/10-08/10   Funktionsoberärztin; Abt. Gastroenterologie und Endokrinologie, UMG
- 09/04-03/06   Anschubfinanzierung UMG
- 09/02-04/10   Assistenzärztin und wissenschaftliche Assistentin; Abt. Gastroenterologie und Endokrinologie; Universitätsmedizin Göttingen (UMG)
- 04/2010       Fachärztin für Gastroenterologie
- 09/2008       Fachärztin für Innere Medizin
- 06/00-08/02   Postdoktoranden-Stipendium der Alexander von Humboldt-Stiftung und der Japan Society for the Promotion of Science; Kitasato Institute for Oriental Medicine (Prof. Dr. med. T. Hanawa) und Abt. für Biochemie und Biomedizinische Forschung (Prof. Dr. med. M. Suematsu / Prof. Dr. med. K. Watanabe), Keio Universität, beide Tokio, Japan
- 03/98-05/00   Ärztin im Praktikum und Assistenzärztin; Med. Klinik Innenstadt, LMU München (Prof. Dr. med. P. Scriba)
- 09/1999       Approbation, LMU München
- 02/1999       Promotion zum Dr. med.  
Titel der Doktorarbeit: Regulation der TGF- $\beta$ 1- und bFGF-mRNA-Expression in isolierten Schweineschilddrüsenfollikeln in vitro mit Wachstumsfaktoren, Jod, oder  $\delta$ -Jodlaktone (bei Prof. Dr. med. R. Gärtner, Endokrinologie, LMU München)
- 07/1998       Magister in ND, Kunstgeschichte und Psychiatrie (Wahlfach aus der Medizin)  
Titel der Magisterarbeit: Verständnis von "Wissenschaft" in den Prosaarbeiten Thomas Bernhards (bei Prof. Dr. phil. Georg Jäger, Institut für Deutsche Philologie, LMU München)
- 04/1997       Drittes Staatsexamen Humanmedizin Ludwig-Maximilians-Universität München
- 1996           Praktisches Jahr Humanmedizin: LMU München; Hôpital Kremlin-Bicêtre, Paris, (Erasmus-Stipendium); Hôpital Universitaire des Enfants Reine Fabiola, Brüssel
- 1995           Zweites Staatsexamen Humanmedizin
- 1994           Erstes Staatsexamen Humanmedizin; Magister Zwischenprüfung
- 1993           Kunstgeschichte als Nebenfach zu ND, LMU München
- 1992           Physikum, Wechsel an die LMU, München
- 1991           Parallelstudium: Neuere deutsche Literatur, Französisch, Philosophie; Rheinisch-Westfälische Technische Hochschule (RWTH), Aachen
- 1990           Beginn Medizinstudium, RWTH, Aachen
- 1990           Abitur, Otto-Hahn-Gymnasium, Berg. Gladbach/Bensberg

## Sonstige Tätigkeiten

- Seit 01/2019 Editor GIST - Gastrointestinal Stromal Tumor
- Seit 08/2015 Managing Editor der Zeitschrift Digestion
- Seit 2010 Gutachtertätigkeiten für medizinisch-wissenschaftliche Zeitschriften mit Peer Review: Experimental and Molecular Pathology, European Journal of Surgical Oncology, Medical Oncology, Onkologie, Strahlentherapie und Onkologie, Cancer Microenvironment, BMC Gastroenterology, BMC Cancer, World Journal of Gastroenterology, Medical Oncology, Medicine, Fundamental and Clinical Pharmacology, Disease Markers, International Reviews of Immunology, Evidence Based Complementary and Alternative Medicine, The American Journal of Medical Sciences, Nutrition.

## Mitgliedschaften

- seit 2000 Japanese Society for Traditional Oriental Medicine (Kampo Medicine)
- seit 2000 Japan Society for the Promotion of Science (JSPS)
- seit 2004 Dt. Gesellschaft für Verdauungs- und Stoffwechselerkrankungen (DGVS)
- seit 2008 Deutsche Gesellschaft der Humboldtianer e.V.
- seit 2009 International Society for Japanese Kampo Medicine (ISJKM), Präsidentin 09/2019
- seit 2010 Dt. Gesellschaft für Ultraschall in der Medizin (DEGUM)
- seit 2010 Dt. Krebsgesellschaft (DKG)
- seit 2010 Arbeitsgemeinschaft Internistische Onkologie (AIO)
- seit 2012 DIN Normenausschuß Traditionelle Chinesische Medizin (ISO/TC249)
- seit 2017 Gesellschaft für Phytotherapie (GPT), Vorstandmitglied seit 09/2019
- seit 2019 Förderverein der Gesellschaft für fernöstliche Medizin, Präsidentin

# Publikationen

## Originalarbeiten

1. Gärtner R, Schopohl D, Schäfer S, Dugrillon A, Erdmann A, Toda S, Bechtner G. Regulation of Transforming Growth Factor- $\beta$ 1 messenger Ribonucleic Acid Expression in Porcine Thyroid Follicles in vitro by Growth Factors, Iodine, or  $\delta$ -Iodolactone.; *Thyroid* 1997; 7: 633-40
2. Reissenweber H, Schäfer S. Japanische Phytotherapie (Kampo) – Klinische Relevanz und Qualitätssicherung in der Modernen Medizin, Symposium Phytopharmaka VI, June 2000; Proceedings of the German Society for Clinical Pharmacology and Therapy 2001
3. Schäfer S, Kajimura M, Tsuyama S, Uchida K, Sato E, Inoue M, Suematsu M, and Watanabe K. Aberrant utilization of nitric oxide and regulation of soluble guanylate cyclase in rat diabetic retinopathy. *Antioxidant and Redox Signaling* 2003; 5(4): 457-65
4. Cameron S und Ramadori G. Familiäre Gastrointestinale Stromatumoren; *Tumor Diagnostik & Therapie*, Thieme Verlag Stuttgart 2004; 25: 189-191
5. Cameron S, Ramadori G, Füzesi L, Sattler B, Gunawan B, Müller D, Ringe B, Lorf T. Successful liver transplantation in two cases of metastatic gastrointestinal stromal tumors. *Transplantation* 2005; 80: 283-284.
6. Cameron-Schaefer S, Kondo K, Ishige A, Tsuyama S, Uchida K, Hanawa T, Suematsu M, and Watanabe K. Maintaining the redox-balance intact: Gosha-jinki-gan but not insulin activates retinal soluble guanylate cyclase in diabetic rats.; *Ophthalmic Research* 2006; 38: 95-104
7. Matyakhina L, Bei TA, McWhinney SR, Pasini B, Cameron S, Gunawan B, Stergiopoulos SG, Boikos S, Muchow M, Dutra A, Pak E, Campo E, Cid MC, Gomez F, Gaillard RC, Assie G, Füzesi L, Baysal BE, Eng C, Carney JA, Stratakis CA. Genetics of Carney triad: recurrent losses at chromosome 1, but lack of germline mutations in genes associated with paragangliomas and gastrointestinal stromal tumors. *Journal of Clinical Endocrinology and Metabolism* 2007; 92: 2938-2943
8. Cameron S, Haller F, Dudas J, Moriconi F, Gunawan B, Armbrust T, Langer C, Füzesi L, and Ramadori G. Immune cells in primary gastrointestinal stromal tumors. *European Journal of Gastroenterology and Hepatology* 2008; 20: 327-334
9. Haller F, Löbke C, Ruschhaupt M, Cameron S, Schulten H, Schwager S, Heydebreck A, Gunawan B, Langer C, Ramadori G, Sülthmann H, Poustka A, Korf U, Füzesi L. Loss of 9p leads to p16INK4A downregulation and enables RB/E2F1-dependent cell cycle promotion in gastrointestinal stromal tumours (GISTs). *Journal of Pathology* 2008; 215:253-262
10. Homayounfar K, Gunawan B, Cameron S, Haller F, Baumhoer D, Uecker S, Sander B, Ramadori G, Lorf T, Füzesi L. Pattern of chromosomal aberrations in primary liver cancers identified by comparative genomic hybridisation. *Human Pathology* 2009; 40: 834-842
11. Armbrust T, Sobotta M, Haller F, Gunawan B, Füzesi L, Langer C, Cameron S, Ramadori G. Does Imatinib turn recurrent and/or metastasized gastrointestinal stromal tumors into a chronic disease? – Single center experience. *European Journal of Gastroenterology and Hepatology* 2009; 21: 819-823.
12. Mansuroglu T, Baumhoer D, Dudas J, Haller F, Cameron S, Lorf T, Füzesi L, Ramadori G. Expression of stem cell factor (SCF) receptor c-kit in human non-tumoral and tumoral hepatic cells. *European Journal of Gastroenterology and Hepatology* 2009; 21: 1206-1211.

13. Cameron S, Ramadori G. Gastrointestinal stromal tumors: diagnostics, therapy and beyond? *Minerva Gastroenterol Dietol.* 2009; 55(4):409-423.
14. Cameron S, Hünerbein D, Mansuroglu T, Armbrust T, Scharf JG, Schwörer H, Füzesi L, Ramadori G. Response of the primary tumor in symptomatic and asymptomatic stage IV colorectal cancer to combined interventional endoscopy and palliative chemotherapy. *BMC Cancer* 2009;9(1):218
15. Cameron S, Savvoukidis T, Armbrust T, Haller F, Kitz J, Fúzesi L, Ramadori G. Analysis of a case with disappearance of the primary gastrointestinal stromal tumor and progressive liver metastases under long-term treatment with tyrosine kinase inhibitors. *Medical Oncology* 2010; 27:213-218.
16. Haller F, Agaimy A, Cameron S, Beyer M, Gunawan B, Happel N, Langer C, Ramadori G, von Heydebreck A, Füzesi L. Expression of p16INK4A in gastrointestinal stromal tumours (GISTs): two different forms exist that independently correlate with poor prognosis. *Histopathology* 2010; 56:305-318.
17. Ramadori G, Cameron S. Effects of systemic chemotherapy on the liver. *Annals of Hepatology* 2010; 9:133-143
18. Amanzada A, Töppler GJ, Cameron S, Schwörer H, Ramadori G. A case report of a patient with hereditary hemorrhagic telangiectasia treated successively with thalidomide and bevacizumab. *Case Reports in Oncology* 2010;3(3):463-70
19. Ramadori G, Cameron S, Tschene B. Long-Lasting tumor response in patients with panitumumab monotherapy for chemorefractory metastatic colorectal carcinoma – A report of two cases. *Case Reports in Oncology* 2010; 3:154-159
20. Schaefer IM, Schüler P, Enders C, Scharf JG, Cameron S, Ramadori G, Füzesi L. High chromosomal instability in adenocarcinoma of the ileum arising in multifocal gastric heterotopia with gastritis cystica profunda.; *Medical Oncology*; 2011;28(4):1023-6.
21. Cameron S. Lebererkrankungen im Alter, weniger aggressiv behandeln? *MedReview* 14;2011: 11-13
22. Haller F, Cortis J, Helfrich J, Cameron S, Schüler P, Schwager S, Gunawan B, Füzesi L, Agaimy A. Epithelioid/mixed phenotype in gastrointestinal stromal tumors with KIT mutation from the stomach is associated with accelerated passage of late phases of the cell cycle and shorter disease-free survival. *Modern Pathology* 2011; 24:248-255
23. Blaschke M, Cameron S, Emami K, Blumberg J, Wegner U, Nischwitz M, Ramadori G. Measurement of 5-FU plasma levels in patients with advanced cancer: correct approach to practical procedures is essential. *International Journal of Clinical Pharmacology and Therapy* 2011; 49:83-85
24. Streit F, Binder L, Hafke A, Brandhorst G, Bräulke F, Haase D, Armbrust T, Cameron S, Ramadori G, Oellerich M, Walson P. Use of total and unbound imatinib and metabolite LC-MS/MS assay to understand individual responses in CML and GIST patients. *Therapeutic Drug Monitoring* 2011; 33(5):632-43
25. Schaefer IM, Enders C, Polten A, Haller F, Frölich AM, Cameron S, Schüler P, Schweiger P, Gunawan B, Beham A, Füzesi L. Common genomic aberrations in basaloid squamous cell

- carcinoma and carcinosarcoma of the esophagus detected by CGH and array CGH. *American Journal of Clinical Pathology* 2011; 135(4):579-586.
26. Cameron S, Schaefer IM, Schwoerer H, Ramadori G. Ten Years of Treatment with 400 mg Imatinib per Day in a Case of Advanced Gastrointestinal Stromal Tumor. *Case Reports in Oncology* 2011; 4(3):505-511
  27. Blaschke M, Cameron S, Emami K, Blumberg J, Wegner U, Nischwitz M, Ramadori G. Measurements of 5-FU Plasma Concentrations in Patients with Gastrointestinal Cancer: 5-FU Levels Reflect the 5-FU Dose Applied. *Journal of Cancer Therapy* 2011; doi:10.4236/jct.2011
  28. Cameron S, Schwartz A, Sultan S, Schaefer IM, Hermann R, Rave-Fränk M, Hess CF, Christiansen H, Ramadori G. Radiation-induced damage in different segments of the rat intestine after external beam irradiation of the liver. *Experimental Journal of Pathology* – 2012; 92:243-258.
  29. Beham AW, Schaefer IM, Schüler P, Cameron S, Ghadimi BM. Gastrointestinal stromal tumors. *Int J Colorectal Dis.* 2012;27(6):689-700
  30. Schaefer IM, **Cameron S**, Middel P, Homayounfar K, Schwörer H, Vieth M, Veits L. Pyloric gland adenoma of the cystic duct with malignant transformation: report of a case with a review of the literature. *BMC Cancer* 2012 Dec 4;12:570.
  31. Beham A, Schaefer IM, Cameron S, von Hammerstein K, Füzesi L, Ramadori G, Ghadimi M. Duodenal GIST: A single center experience; *International Journal of Colorectal disease* 2013; 28(4):581-90.
  32. Blaschke M, **Cameron S**, Goeschen C, Ramadori G. 5-FU schedules, serum 5-FU levels and their relationship to therapy response and toxicity in patients with gastrointestinal cancer. *Int J Clin Pharmacol Ther* 2013 Jan;51(1):56-8.
  33. Sultan S, Cameron S, Ahmad S, Martius G, Malik IA, Schultze FC, Rave-Fränk M, Christiansen H, Ramadori G. Serum lipocalin-2 is a potential biomarker of liver but not lung irradiation. *Liver Int* 2013 Mar;33(3):459-68.
  34. Hupfeld T, Chapuy B, Schrader V, Beutler M, Veltkamp C, Koch R, **Cameron S**, Aung T, Haase D, Larosee P, Truemper L, Wulf GG. Tyrosinekinase inhibition facilitates cooperation of transcription factor SALL4 and ABC transporter A3 towards intrinsic CML cell drug resistance. *Br J Haematol* 2013; 161:204-213.
  35. Rave-Fraenk M, Malik I, Christiansen H, Naz N, Sultan S, Amanzada A, Blaschke M, Cameron S, Ahmad S, Ramadori G, Moriconi F. Rat model of fractionated (2Gy/day) 60 Gy irradiation of the liver: long-term effects. *Radiat Environment Biophys* 2013;52(3):321-38
  36. Homayounfar K, Schwarz A, Enders C, Cameron S, Baumhoer D, Ramadori G, Lorf T, Gunawan B, Sander B. Etiologic influence on chromosomal aberrations in European hepatocellular carcinoma identified by CGH. *Pathol Res Pract.* 2013;209(6):380-7
  37. Goralczyk AD, Cameron S, Amanzada A. Treatment of chronic HCV genotype 1 infection with telaprevir: a Bayesian mixed treatment comparison of fixed-length and response-guided treatment regimens in treatment-naive and --experienced patients. *BMC Gastroenterol.* 2013;13(1):148

38. Naz N, Ahmad S, Cameron S, Moriconi F, Rave-Fränk M, Christiansen H, Hess CF, Ramadori G, Malik IA. Differential Regulation of Ferritin Subunits and Iron Transport Proteins: An Effect of Targeted Hepatic X-Irradiation. *BioMed Research International* 2013, doi.org/10.1155/2013/353106
39. Schaefer IM, Delfs C, Cameron S, Gunawan B, Agaimy A, Ghadimi BM, Haller F. Chromosomal aberrations in primary PDGFRA-mutated gastrointestinal stromal tumors. *Hum Pathol.* 2014;45(1):85-97
40. Amanzada A, Moriconi F, Mansuroglu T, Cameron S, Ramadori G, A Malik I. Induction of chemokines and cytokines before neutrophils and macrophage recruitment in different regions of rat liver after TAA administration. *Lab Invest.* 2014;94:235-247
41. Schaefer IM, Ströbel P, Cameron S, Beham A, Otto C, Schildhaus HU, Agaimy A. Rhabdoid morphology in gastrointestinal stromal tumours (GISTs) is associated with PDGFRA mutations but does not imply aggressive behavior. *Histopathology* 2014;64:421-430
42. Tsaknakis B, Schaefer IM, Schwörer H, Sahlmann CO, Thoms KM, Blaschke M, Ramadori G, Cameron S. Long-lasting complete response of metastatic melanoma to ipilimumab with analysis of the resident immune cells. *Med Oncol.* 2014;31(1):813.
43. Ahmad S, Sultan S, Naz N, Ahmad G, Alwahsh SM, Cameron S, Moriconi F, Ramadori G, Malik IA. Regulation of Iron Uptake in Primary Culture Rat Hepatocytes: The Role of Acute Phase Cytokines. *Shock.* 2014;41:337-345.
44. Khan S, Cameron S, Blaschke M, Moriconi F, Naz N, Amanzada A, Ramadori G, Malik IA. Differential gene expression of chemokines in KRAS and BRAF mutated colorectal cell lines: Role of cytokines. *World Journal of Gastroenterology* 2014, 20:2979-2994.
45. Cameron S, Gieselmann M, Blaschke M, Ramadori G, Füzesi L. Immune cells in primary and metastatic gastrointestinal stromal tumors (GIST). *Int J Clin Exp Pathol* 2014; 7: 3563-3579
46. Amanzada A, Goralczyk AD, Reinhardt L, Moriconi F, Cameron S, Mihm S. Erythropoietin rs1617640 G allele associates with an attenuated rise of serum erythropoietin and a marked decline of hemoglobin in hepatitis C patients undergoing antiviral therapy. *BMC Infect Dis* 2014;14:503.
47. Mechie NC, Röver C, Cameron S, Amanzada A. Predictability of IL-28B-polymorphism on protease-inhibitor-based triple-therapy in chronic HCV-genotype-1 patients: A meta-analysis. *World J Hepatol* 2014;6(10):759-65.
48. Haller F, Zhang JD, Moskalev EA, Braun A, Otto C, Geddert H, Riazalhosseini Y, Ward A, Balwierz A, Schaefer IM, Cameron S, Ghadimi BM, Agaimy A, Fletcher JA, Hoheisel J, Hartmann A, Werner M, Wiemann S, Sahin O. Combined DNA methylation and gene expression profiling in gastrointestinal stromal tumors (GISTs) reveals hypomethylation of SPP1 as an independent prognostic factor. *Int J Cancer* 2015; 136:1013-1023.
49. Martius G, Cameron S, Rave-Fränk M, Hess CF, Wolff HA, Malik IA. The Anti-TNF- $\alpha$  Antibody Infliximab Inhibits the Expression of Fat-Transporter-Protein FAT/CD36 in a Selective Hepatic-Radiation Mouse Model; *Int J Mol Sci* 2015; 16:4682-4697.

50. Malik IA, Stange I, Martius G, Cameron S, Rave-Fränk M, Hess CF, Ellenrieder V, Wolff HA. Role of PECAM-1 in radiation-induced liver inflammation. *J Cell Mol Med* 2015; 19: 2441-2452.
51. Agaimy A, Bauer S, Beham A, Bertolini J, Haller F, Koschny R, Maier J, Montemurro M, Perez D, Schaefer IM, Schildhaus HU, Wurst C, Cameron S. Gastrointestinal Stromal Tumours (GIST) - development in pathology, surgery and medical therapy. *Z Gastroenterol.* 2015; 53(3):235-43.
52. Cameron S. Gastrointestinaler Stromatumor (GIST). *Gastroenterologie up2date* 11;2015 doi.org/10.1055/s-0034-1392312.
53. Sultan S, Ahmad S, Rave-Fränk M, Malik IA, Hess CF, Christiansen H, Cameron S. Induction of Lipocalin 2 in a Rat Model of Lung Irradiation. *Int J Mol Sci* 2016; 17: E637. doi: 10.3390/ijms17050637.
54. Eriksson M, Reichardt P, Sundby Hall K, Schütte J, Cameron S, Hohenberger P, Bauer S, Leinonen M, Reichardt A, Rejmyr Davis M, Alvegard T, Joensuu H. Needle biopsy through the abdominal wall for the diagnosis of gastrointestinal stromal tumour – Does it increase the risk for tumour cell seeding and recurrence? *Eur J Cancer* 2016; 59:128-133.
55. Merten L, Agaimy A, Moskalev EA, Giedl J, Kayser C, Geddert H, Schaefer IM, Cameron S, Werner M, Ströbel P, Hartmann A, Haller F. Inactivating Mutations of RB1 and TP53 Correlate With Sarcomatous Histomorphology and Metastasis/Recurrence in Gastrointestinal Stromal Tumors. *Am J Clin Pathol* 2016; 146:718-726.
56. Joensuu H, Wardelmann E, Sihto H, Eriksson M, Sundby Hall K, Reichardt A, Hartmann JT, Pink D, Cameron S, Hohenberger P, Al-Batran SE, Schlemmer M, Bauer S, Nilsson B, Kallio R, Junnila J, Vehtari A, Reichardt P. Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial. *JAMA Oncol.* 2017 Mar 23. doi: 10.1001/jamaoncol.2016.5751.
57. He YJ, Kuchta K, Deng YM, Cameron S, Lin Y, Liu XY, Ye GR, Lv X, Kobayashi Y, Shu JC. Curcumin Promotes Apoptosis of Activated Hepatic Stellate Cells by Inhibiting Protein Expression of the MyD88 Pathway. *Planta Med* 2017. doi:10.1055/s-0043-113044.
58. Moskalev E, Bureira, Braun A, Kayser C, Geddert H, Schaefer IM, Cameron S, Ghadimi M, Stroebel P, Werner A, Martin W, Hartmann A, Wiemann S, Haller F. The expression of hematopoietic progenitor cell antigen CD34 is regulated by DNA methylation in a sitedependent manner in gastrointestinal stromal tumours (GISTs). *Int J Can* 2017; 141(11):2296-2304.
59. Cameron S, Beham A, Schildhaus H-U. Current standard and future perspectives in the treatment of gastrointestinal stromal tumors (GIST). *Digestion*; 2017: DOI: 10.1159/000455835.
60. Reichardt P, Reichardt A, Cameron S. Gastrointestinale Stromatumoren (GIST). *Der Gastroenterologe*; 2017: DOI 10.1007/s11377-016-0131-3.
61. Ahmad S, Cameron S, Naz N, Moriconi F. Mediators of hypoxia in a rat model of sterileinduced acute liver injury. *Int J Clin Exp Pathol* 2017; 10(12):11471-11479.

62. Flemming J, Cameron S. Small bowel capsule endoscopy. Indications, results, and clinical benefit in a University environment. *Medicine* 2018; 97:e0148.
63. Cameron S, Kuchta K, Reissenweber-Hewel H. Kampo-Medizin in der gastrointestinalen Onkologie. *Zkm* 2018; 3:50-57.
64. Cameron S. Long-term adjuvant treatment of gastrointestinal stromal tumors (GIST) with imatinib – a comment and reflection on the PERSIST-5 study. *Transl Gastroenterol Hepatol* 2018;3:16.doi:21037/tgh.2018.03.01
- 65a. Cameron S. Gastrointestinale Stromatumore. Bedeutung der Molekularen Diagnostik für Prognose und Therapie. *Der Gastroenterologe* 2018; epub 5-2018/16064340
- 65b. Cameron S. Gastrointestinale Stromatumore. Bedeutung der Molekularen Diagnostik für Prognose und Therapie. *Wien klin Mag*; 2018: DOI 10.1007/s00740-018-0257-7
66. Sander B, Cameron S, Gunawan B, Füzesi L. Optimal thresholds of risk parameters for gastrointestinal stromal tumors. *Eur J Surg Oncol* 2019; doi: 10.1016/j.ejso.2019.08.009.
67. Mechie NC, Mavropoulou E, Ellenrieder V, Kunsch S, Cameron S, Amanzada A. Distinct association of serum vitamin D concentration with disease activity and trough levels of infliximab and adalimumab in inflammatory bowel disease treatment. *Digestion* 2019;3-9. doi.org/10.1159/000502515.
68. Joensuu H, Eriksson M, Sundby Hall K, Reichardt A, Hermes B, Schuette J, Cameron S, Hohenberger P, Jost P, Al-Batran S-E, Lindner LH, Bauer S, Wardelmann E, Nilsson BE, Kallio RS, Jaakkola P, Junnila J, Alvegard T, Reichardt P. Three versus one year of adjuvant imatinib for high-risk gastrointestinal stromal tumor (GIST): Survival analysis of a randomized trial after 10 years of follow-up. *Journal of Clinical Oncology* 2020; 38:15 suppl. 11503-11503; doi: 10.1200/JCO.2020.38.15.
69. Kuchta K, Cameron S. Phytotherapy for Cachexia: Where do we stand? *Frontiers in Pharmacology* 2020: 11; Article 917. <https://doi.org/10.3389/fphar.2020.00917>

#### Editorials, Kommentare und Letter

1. Schäfer S. Kampo – Japanische Phytotherapie; Symposium Medical – Naturheilkunde; BMV Berliner Medizinische Verlagsanstalt GmbH 2001; 11. Jahrgang: 38-39
2. Schäfer S und Ramadori G. Vom Adenom zum Karzinom – Wie festgefahren sind die Wege der Mutationen? *Zeitschrift für Gastroenterologie* 2003; 41: 201-03.
3. Cameron S, Ramadori G. Beitrag der Gastroenterologie zur Therapie – 15 Jahre Erfahrung: aus der Vielfalt Hoffnung schöpfen. *Glandula-NET Jubiläumsausgabe* 2010
4. Cameron S, Reissenweber H, Watanabe K. Asian medicine: Japan's paradigm; *Nature*. 2012 Feb 1;482(7383):35. doi: 10.1038/482035a.

#### Buchbeiträge

Möhler M., Cameron S, Menges M. Magentumore / GIST. Kapitel 3.4, in: *Rationelle Diagnostik und Therapie in der Inneren Medizin, Leitlinien-basierte Empfehlungen für die Praxis*; Elsevier, Urban&Fischer, 2012 ISBN 978.3-437-22827-8. Hrgs. Busse O, Fleig WE, Mayet WJ, Mertens PR, Meyer J, Müller OA, et al. Aktualisierung 2020; in Press.